Kidney International

Journal

Publication Venue For

  • Avian erythroblastosis virus E26 oncogene homolog-1 (ETS-1) plays a role in renal microvascular pathophysiology in the Dahl salt-sensitive rat.  97:528-537. 2020
  • TLR9 activation induces aberrant IgA glycosylation via APRIL- and IL-6–mediated pathways in IgA nephropathy.  97:340-349. 2020
  • Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease.  96:1030-1036. 2019
  • FGF23 and inflammation—a vicious coalition in CKD.  96:813-815. 2019
  • SON haploinsufficiency causes impaired pre-mRNA splicing of CAKUT genes and heterogeneous renal phenotypes..  95:1494-1504. 2019
  • Health-related quality of life in glomerular disease.  95:1209-1224. 2019
  • Long-term trajectory of kidney function in autosomal-dominant polycystic kidney disease.  95:1253-1261. 2019
  • Implementing core outcomes in kidney disease: report of the Standardized Outcomes in Nephrology (SONG) implementation workshop.  94:1053-1068. 2018
  • Secondary IgA nephropathy.  94:674-681. 2018
  • Genome-wide association studies suggest that APOL1-environment interactions more likely trigger kidney disease in African Americans with nondiabetic nephropathy than strong APOL1–second gene interactions.  94:599-607. 2018
  • FGF23 effects on the heart—levels, time, source, and context matter.  94:7-11. 2018
  • A more direct way to measure glomerular albumin permeability—even in human glomeruli!.  93:1035-1037. 2018
  • APOL1 nephropathy risk variants do not associate with subclinical atherosclerosis or left ventricular mass in middle-aged black adults.  93:727-732. 2018
  • Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease.  93:691-699. 2018
  • Race but not Hepatitis C co-infection affects survival of HIV+ individuals on dialysis in contemporary practice.  93:706-715. 2018
  • Expanding the use of hepatitis C–viremic kidney donors.  92:1031-1033. 2017
  • Image texture features predict renal function decline in patients with autosomal dominant polycystic kidney disease.  92:1206-1216. 2017
  • APOL1 genetic variants are not associated with longitudinal blood pressure in young black adults.  92:964-971. 2017
  • GlucoCEST magnetic resonance imaging in vivo may be diagnostic of acute renal allograft rejection.  92:757-764. 2017
  • The Authors Reply.  91:1256. 2017
  • Renal xenotransplantation: experimental progress and clinical prospects.  91:790-796. 2017
  • Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease.  91:711-719. 2017
  • Obesity increases the risk of end-stage renal disease among living kidney donors.  91:699-703. 2017
  • Screening, diagnosis, and management of patients with Fabry disease: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.  91:284-293. 2017
  • Evidence from the Oxford Classification cohort supports the clinical value of subclassification of focal segmental glomerulosclerosis in IgA nephropathy.  91:235-243. 2017
  • Chronic massive pneumoperitoneum.  90:1386. 2016
  • Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease.  90:985-996. 2016
  • C-reactive protein promotes acute kidney injury via Smad3-dependent inhibition of CDK2/cyclin E.  90:610-626. 2016
  • Deletion of mineralocorticoid receptors in smooth muscle cells blunts renal vascular resistance following acute cyclosporine administration.  89:354-362. 2016
  • Ligand trap for the activin type IIA receptor protects against vascular disease and renal fibrosis in mice with chronic kidney disease.  89:1231-1243. 2016
  • Loss of Glis2/NPHP7 causes kidney epithelial cell senescence and suppresses cyst growth in the Kif3a mouse model of cystic kidney disease.  89:1307-1323. 2016
  • The MEST score provides earlier risk prediction in lgA nephropathy.  89:167-175. 2016
  • Migrated intra-jejunal peritoneal dialysis catheter.  88:1457. 2015
  • Cell-based immunosuppression in kidney transplantation: The value of non-human primate studies.  88:1196-1197. 2015
  • Renal systems biology of patients with systemic inflammatory response syndrome.  88:804-814. 2015
  • Deceased donor multidrug resistance protein 1 and caveolin 1 gene variants may influence allograft survival in kidney transplantation.  88:584-592. 2015
  • Appendiceal tissue confirmation of Fabry's disease.  88:417. 2015
  • A comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease.  88:146-151. 2015
  • Autosomal-dominant polycystic kidney disease (ADPKD): Executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.  88:17-27. 2015
  • Macrophage and epithelial cell H-ferritin expression regulates renal inflammation.  88:95-108. 2015
  • Obesity, metabolic health, and the risk of end-stage renal disease.  87:1216-1222. 2015
  • Should kidney donors be genotyped for APOL1 risk alleles?.  87:671-673. 2015
  • The use of immunoglobulin light chain assays in the diagnosis of paraprotein-related kidney disease.  87:692-697. 2015
  • Kidney transplant results in children: Progress made, but blacks lag behind.  87:492-494. 2015
  • A closer look at rituximab induction on HLA antibody rebound following HLA-incompatible kidney transplantation.  87:409-416. 2015
  • Ethical challenges with hemodialysis patients who lack decision-making capacity: Behavioral issues, surrogate decision-makers, and end-of-life situations.  86:475-480. 2014
  • Factors influencing clinical outcome in patients with primary hyperoxaluria type 1.  86:1074-1076. 2014
  • Kidney donors at increased risk? Additional studies are needed.  86:650. 2014
  • Kidney xenotransplantation.  85:265-275. 2014
  • Neither pre-transplant rituximab nor splenectomy affects de novo HLA antibody production after renal transplantation.  85:425-430. 2014
  • Relative risks of chronic kidney disease for mortality and end-stage renal disease across races are similar.  86:819-827. 2014
  • The high cost of organ transplant commercialism.  86:858-859. 2014
  • Predicting dialysis vascular access blood flow and diameter: Too much, too little, or just right.  84:1076-1078. 2013
  • The IgA1 immune complex-mediated activation of the MAPK/ERK kinase pathway in mesangial cells is associated with glomerular damage in IgA nephropathy.  82:1284-1296. 2012
  • A reproducible mouse model of chronic allograft nephropathy with vasculopathy.  82:1231-1235. 2012
  • Delayed ischemic preconditioning contributes to renal protection by upregulation of miR-21.  82:1167-1175. 2012
  • Of veins, valves, and vascular access!.  82:1236-1237. 2012
  • The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression.  82:790-796. 2012
  • In vivo regulation of the heme oxygenase-1 gene in humanized transgenic mice.  82:278-291. 2012
  • Regarding Maas's editorial letter on serum suPAR levels..  82:492. 2012
  • Sodium nitrite protects against kidney injury induced by brain death and improves post-transplant function.  82:304-313. 2012
  • Critical care nephrology: Management of acid-base disorders with CRRT.  82:9-18. 2012
  • Sugars and alcohol: IgA-associated renal diseases in alcoholic cirrhosis.  80:1252-1254. 2011
  • Hydrogen sulfide inhibits the calcification and osteoblastic differentiation of vascular smooth muscle cells.  80:731-739. 2011
  • Elevated depressive affect is associated with adverse cardiovascular outcomes among African Americans with chronic kidney disease.  80:670-678. 2011
  • Validation of the Oxford classification of IgA nephropathy.  80:310-317. 2011
  • Warfarin-related nephropathy: Another newly recognized complication of an old drug.  80:131-133. 2011
  • Aberrant glycosylation of IgA1 is inherited in both pediatric IgA nephropathy and Henoch-Schönlein purpura nephritis.  80:79-87. 2011
  • Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease.  79:1370-1378. 2011
  • Mineralocorticoid receptor activation and blockade: An emerging paradigm in chronic kidney disease.  79:1051-1060. 2011
  • Vitamin D deficiency and anemia in early chronic kidney disease.  77:715-720. 2010
  • Sociodemographic factors contribute to the depressive affect among African Americans with chronic kidney disease.  77:1010-1019. 2010
  • Genotype-phenotype correlation in primary hyperoxaluria type 1: The p.Gly170Arg AGXT mutation is associated with a better outcome.  77:443-449. 2010
  • Acute kidney injury in sepsis: Questions answered, but others remain.  77:485-487. 2010
  • Hydrogen: Another gas with therapeutic potential.  77:85-87. 2010
  • Protective role of extracellular superoxide dismutase in renal ischemia/reperfusion injury.  78:374-381. 2010
  • Renal CD14 expression correlates with the progression of cystic kidney disease.  78:550-560. 2010
  • Response to Targeting hyperphosphatemia: Truth or dare.  77:257. 2010
  • Simulation of real-time ultrasound-guided renal biopsy.  78:705-707. 2010
  • The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults.  77:921-927. 2010
  • The authors reply.  77:930. 2010
  • The authors reply.  77:743-744. 2010
  • A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease.  76:705-716. 2009
  • The Oxford classification of IgA nephropathy: Pathology definitions, correlations, and reproducibility.  76:546-556. 2009
  • The Oxford classification of IgA nephropathy: Rationale, clinicopathological correlations, and classification.  76:534-545. 2009
  • Complications impair the usefulness and validity of the rat tail arteriovenous fistula model.  76:916. 2009
  • Effect of conservative treatment on the renal outcome of children with primary hyperoxaluria type 1.  76:767-773. 2009
  • Neutrophils in acute kidney injury: Not neutral any more.  75:674-676. 2009
  • Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): Review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989-2008).  75. 2009
  • Uromodulin storage disease.  73:971-976. 2008
  • Overexpression of innate immune response genes in a model of recessive polycystic kidney disease.  73:63-76. 2008
  • Prevalence and severity of disordered mineral metabolism in Blacks with chronic kidney disease.  73:956-962. 2008
  • Response to 'Overexpression of complement-component genes in Han:SPRD rats a model of polycystic kidney disease'.  73:1325. 2008
  • Vitamin D levels and early mortality among incident hemodialysis patients.  72:1004-1013. 2007
  • Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels.  71:1148-1154. 2007
  • When to refer patients with chronic kidney disease for vascular access surgery: Should age be a consideration?.  71:555-561. 2007
  • Emphysematous pyelonephritis.  71:462-465. 2007
  • HOpe for contrast-induced acute kidney injury.  72:907-909. 2007
  • Impact of obesity on arteriovenous fistula outcomes in dialysis patients.  71:39-43. 2007
  • Refractory hyponatremia.  71:79-82. 2007
  • Hydroxyproline ingestion and urinary oxalate and glycolate excretion.  70:1929-1934. 2006
  • Puromycin aminonucleoside induces oxidant-dependent DNA damage in podocytes in vitro and in vivo.  70:1962-1973. 2006
  • Immunofluorescence on pronase-digested paraffin sections: A valuable salvage technique for renal biopsies.  70:2148-2151. 2006
  • Response to 'Ultrasound surveillance and graft patency' [11].  70:1376. 2006
  • Post-transplant hypophosphatemia: Tertiary 'Hyper-Phosphatoninism'?.  70:1486-1494. 2006
  • Unraveling the relationship between macula densa cell volume and luminal solute concentration/osmolality.  70:865-871. 2006
  • Response to p-Cresol for better or worse: But what are we measuring? [5].  70:232-233. 2006
  • Cellular mechanisms of WNK4-mediated regulation of ion transport proteins in the distal tubule.  69:2116-2118. 2006
  • Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure.  69:1806-1813. 2006
  • Unearthing uric acid: An ancient factor with recently found significance in renal and cardiovascular disease.  69:1722-1725. 2006
  • Outcomes of thrombosed arteriovenous grafts: Comparison of stents vs angioplasty.  69:934-937. 2006
  • Randomized comparison of ultrasound surveillance and clinical monitoring on arteriovenous graft outcomes.  69:730-735. 2006
  • 3-5 year longitudinal follow-up of pediatric patients after acute renal failure.  69:184-189. 2006
  • Hemodialysis reduces inhibitory effect of plasma ultrafiltrate on LDL oxidation and subsequent endothelial reactions.  69:144-151. 2006
  • Outcomes of tunneled femoral hemodialysis catheters: Comparison with internal jugular vein catheters.  68:2886-2889. 2005
  • Questions about graft surveillance [3].  68:2401-2402. 2005
  • Prevalence of chronic kidney disease and anemia among participants in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort study: Baseline results.  68:1427-1431. 2005
  • Racial differences in renal arteriolar structure in children with minimal change nephropathy.  68:1154-1160. 2005
  • IgA1-containing immune complexes in IgA nephropathy differentially affect proliferation of mesangial cells.  67:504-513. 2005
  • Dialysis dose and the effect of gender and body size on outcome in the HEMO Study.  65:1386-1394. 2004
  • Hydrogen peroxide mediates FK506-induced cytotoxicity in renal cells.  65:139-147. 2004
  • Hypothesis: Uric acid, nephron number, and the pathogenesis of essential hypertension.  66:281-287. 2004
  • The impact of serum uric acid on cardiovascular outcomes in the LIFE study.  65:1041-1049. 2004
  • Thrombospondin-1 is a major activator of TGF-β in fibrotic renal disease in the rat in vivo.  65:459-468. 2004
  • Lipoproteins in the DCCT/EDIC cohort: Associations with diabetic nephropathy.  64:817-828. 2003
  • Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort.  64:1035-1045. 2003
  • The FcγRIIIA-F158 allele is a risk factor for the development of lupus nephritis: A meta-analysis.  63:1475-1482. 2003
  • Gender differences in outcomes of arteriovenous fistulas in hemodialysis patients.  63:346-352. 2003
  • Sodium ferric gluconate complex in hemodialysis patients. Ii. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients.  63:217-224. 2003
  • Increasing arteriovenous fistulas in hemodialysis patients: problems and solutions..  62:1109-1124. 2002
  • Cytoprotection of pancreatic islets before and early after transplantation using gene therapy.  61:S79-S84. 2002
  • Increasing arteriovenous fistulas in hemodialysis patients: Problems and solutions.  62:1109-1124. 2002
  • Interactions of human mesangial cells with IgA and IgA-containing immune complexes.  62:465-475. 2002
  • Novel erythropoiesis-stimulating protein in the management of the anemia of chronic renal failure.  62:720-729. 2002
  • Sodium ferric gluconate complex in hemodialysis patients: Adverse reactions compared to placebo and iron dextran.  61:1830-1839. 2002
  • Contribution of dietary oxalate to urinary oxalate excretion.  59:270-276. 2001
  • Cytochrome c mediates apoptosis in hypertensive nephrosclerosis in Dahl/Rapp rats.  59:662-672. 2001
  • Effect of preoperative sonographic mapping on vascular access outcomes in hemodialysis patients.  60:2013-2020. 2001
  • Increased dietary salt accelerates chronic allograft nephropathy in rats.  59:1149-1157. 2001
  • Nitric oxide and Bartter and Gitelman syndromes.  60:1197-1198. 2001
  • Simplified citrate anticoagulation for continuous renal replacement therapy.  60:370-374. 2001
  • Factors associated with the prevalence of arteriovenous fistulas in hemodialysis patients in the HEMO study. Hemodialysis (HEMO) Study Group..  58:2178-2185. 2000
  • Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis Study..  58:1703-1710. 2000
  • Arteriovenous fistula adequacy [3] (multiple letters).  57:347-348. 2000
  • Bacteremia associated with tunneled dialysis catheters: Comparison of two treatment strategies.  57:2151-2155. 2000
  • Factors associated with the prevalence of arteriovenous fistulas in hemodialysis patients in the HEMO study.  58:2178-2185. 2000
  • Induction of apoptosis during development of hypertensive nephrosclerosis.  58:2007-2017. 2000
  • Dynamics of E-cadherin and γ-catenin complexes during dedifferentiation of polarized MDCK cells.  56:910-921. 1999
  • Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure.  55:2423-2432. 1999
  • Predictors of adequacy of arteriovenous fistulas in hemodialysis patients.  56:275-280. 1999
  • Regulation of endosomal acidification via G1-type protein.  55:2524-2525. 1999
  • Thrombospondin peptides are potent inhibitors of mesangial and glomerular endothelial cell proliferation in vitro and in vivo.  55:2236-2249. 1999
  • A multidisciplinary approach to hemodialysis access: Prospective evaluation.  53:473-479. 1998
  • Dietary salt regulates expression of Tamm-Horsfall glycoprotein in rats.  54:1150-1156. 1998
  • Liddie syndrome: An autosomal dominant form of human hypertension.  53:18-24. 1998
  • Low Na+ diet inhibits Na+ and water transport response to vasopressin in rat cortical collecting duct.  54:180-187. 1998
  • Regulation of macula densa Na:H exchange by angiotensin II.  54:2021-2028. 1998
  • Antibodies to C1q in systemic lupus erythematosus: Characteristics and relation to FcγRIIA alleles.  52:1375-1380. 1997
  • Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG.  52:509-516. 1997
  • Glomerular and vascular tissues do not down-regulate nitric oxide synthesis during protracted endotoxemia.  52:460-467. 1997
  • Altered sodium-calcium exchange in afferent arterioles of the spontaneously hypertensive rat.  50:1889-1896. 1996
  • Angiotensin converting enzyme gene polymorphism: Potential silencer motif and impact on progression in IgA nephropathy.  49:571-577. 1996
  • Characterization of sodium-calcium exchange in rabbit renal arterioles.  50:1856-1862. 1996
  • Diversity and regulation of amiloride-sensitive Na+ channels.  49:1632-1637. 1996
  • Functional correction of renal defects in a mouse model for ARPKD through expression of the cloned wild-type Tg737 cDNA.  50:1240-1248. 1996
  • Isolation and characterization of luminal and basolateral plasma membrane vesicles from the medullary thick ascending loop of Henle.  50:1051-1057. 1996
  • Possible role of cytokines on the bone mineral loss in idiopathic hypercalciuria.  49:244-250. 1996
  • cAMP-regulated trafficking of epitope-tagged CFTR.  49:1642-1648. 1996
  • Activation of Na:2Cl:K cotransport by luminal chloride in macula densa cells.  47:752-757. 1995
  • Evidence for apical sodium proton exchange in macula densa cells.  47:746-751. 1995
  • Induction of heme oxygenase in toxic renal injury: A protective role in cisplatin nephrotoxicity in the rat.  48:1298-1307. 1995
  • Adaptive control of anticoagulation during hemodialysis.  45:912-915. 1994
  • Erythropoiesis after withdrawal of enalapril in post-transplant erythrocytosis.  46:1397-1403. 1994
  • Effect of insulin-plus-glucose infusion with or without epinephrine on fasting hyperkalemia.  43:212-217. 1993
  • Relationship of protein intake to urinary oxalate and glycolate excretion.  44:366-372. 1993
  • Shared idiotypes in mesangial deposits in IgA nephropathy are not disease-specific.  44:65-74. 1993
  • Treatment and prevention of hyperkalemia in end-stage renal disease.  43:1197-1209. 1993
  • Binding of serum immunoglobulins to collagens in IgA nephropathy and HIV infection.  42:374-382. 1992
  • Adrenergic modulation of extrarenal potassium disposal in men with end-stage renal disease.  40:1103-1109. 1991
  • Communication between the macula densa cells and the afferent arteriole 1991
  • Determinants of renal microvascular autoregulatory behavior in normal and hypertensive rats 1991
  • IgA nephropathy in blacks: Studies of IgA2 allotypes and clinical course.  39:1218-1224. 1991
  • OKT3 first-dose reaction: Association with T cell subsets and cytokine release.  39:141-148. 1991
  • Transport pathways in macula densa cells 1991
  • Albuterol and insulin for treatment of hyperkalemia in hemodialysis patients.  38:869-872. 1990
  • Insulin in the acute renal adaptation to dietary phosphate restriction in the rat.  37:14-20. 1990
  • Control of serum potassium during fasting in patients with end-stage renal disease.  35:90-94. 1989
  • K-Cl cotransport systems.  36:412-417. 1989
  • Angiotensin influences on tubuloglomerular feedback mechanism in hypertensive rats.  34:631-637. 1988
  • Effects of nonsteroidal antiinflammatory drugs on renal function in sickle cell anemia.  34:500-506. 1988
  • Morphologic alterations of the proximal tubules in light chain-related renal disease.  33:881-889. 1988
  • Uremic acidosis.  34:278-287. 1988
  • Complement activation in IgA nephropathy.  31:1019-1023. 1987
  • Human Bence Jones protein toxicity in rat proximal tubule epithelium in vivo.  32:851-861. 1987
  • Cytomegalovirus glomerulopathy: A controversial lesion.  29:725-733. 1986
  • The sympathetic nervous system in clinical and experimental hypertension.  30:437-452. 1986
  • Cyclic AMP-calcium interaction in the transmission of tubuloglomerular feedback signals.  28:728-732. 1985
  • Effect of urinary pH and diatrizoate on Bence Jones protein nephrotoxicity in the rat.  27:46-50. 1985
  • Complement phenotypes in glomerulonephritis: Increased frequency of homozygous null C4 phenotypes in IgA nephropathy and Henoch-Schonlein purpura.  26:855-860. 1984
  • Dialysis-associated ischemic heart disease: Insights from coronary angiography.  25:653-659. 1984
  • Carbohydrate metabolism during fasting in chronic hemodialysis patients.  24:222-226. 1983
  • Accelerated recovery of single nephron function by the postischemic infusion of ATP-MgCl2.  22:13-20. 1982
  • Acidification in the in vitro perfused tubule.  22:507-518. 1982
  • Luminal and cellular mechanisms for the mediation of tubuloglomerular feedback responses.  22. 1982
  • Relationship between tubulo-glomerular feedback responses and perfusate hypotonicity.  22:234-239. 1982
  • Relationship of coronary risk factors to hemodialysis-associated ischemic heart disease.  22:304-308. 1982
  • Role of a macula densa feedback mechanism as a mediator of renal autoregulation.  22. 1982
  • Enhanced recovery from acute renal failure by the postischemic infusion of adenine nucleotides and magnesium chloride in rats.  17:338-349. 1980
  • Impaired renal blood flow autoregulation in ischemic acute renal failure.  18:68-76. 1980
  • Tubuloglomerular feedback responses during perfusion with nonelectrolyte solutions in the rat.  18:460-471. 1980
  • Biosynthesis of basement membrane matrix by isolated rat renal glomeruli.  15:20-32. 1979
  • Glomerular filtration dynamics in the dog during elevated plasma colloid osmotic pressure.  15:502-512. 1979
  • Ischemic heart disease in patients with uremia undergoing maintenance hemodialysis.  16:600-611. 1979
  • Renal tubular transport and catabolism of proteins and peptides.  16:271-278. 1979
  • Effects of acetazolamide (ACTZ) on total CO2 reabsorption in the rat.  14:753. 1978
  • Influence of vasodilators on glomerular filtration dynamics in the dog.  14:772. 1978
  • Accelerated recovery of acute renal failure by infusion of adenine nucleotides - MgCl2.  12:534. 1977
  • Dual effects of diuretics on volume reabsorption by the proximal tubule.  12:566. 1977
  • Evaluation of the single nephron glomerular filtration coefficient in the dog.  12:137-149. 1977
  • Possible role of osmolality in the mediation of the distal tubular-glomerular feedback responses in the dog.  12:568. 1977
  • International Standard Serial Number (issn)

  • 0085-2538
  • Electronic International Standard Serial Number (eissn)

  • 1523-1755